Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 1
2005 1
2006 5
2007 5
2008 3
2009 6
2010 4
2011 4
2012 3
2013 5
2014 8
2015 4
2016 3
2017 5
2018 4
2019 2
2020 10
2021 9
2022 8
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Dose Equivalents for Antipsychotic Drugs: The DDD Method.
Leucht S, Samara M, Heres S, Davis JM. Leucht S, et al. Among authors: heres s. Schizophr Bull. 2016 Jul;42 Suppl 1(Suppl 1):S90-4. doi: 10.1093/schbul/sbv167. Schizophr Bull. 2016. PMID: 27460622 Free PMC article.
Maintenance treatment with antipsychotic drugs for schizophrenia.
Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM, Leucht S. Ceraso A, et al. Among authors: heres s. Cochrane Database Syst Rev. 2020 Aug 11;8(8):CD008016. doi: 10.1002/14651858.CD008016.pub3. Cochrane Database Syst Rev. 2020. PMID: 32840872 Free PMC article.
Pharmacological treatment of schizophrenia.
Leucht S, Heres S, Kissling W, Davis JM. Leucht S, et al. Among authors: heres s. Fortschr Neurol Psychiatr. 2013 May;81(5):e1-13. doi: 10.1055/s-0033-1335405. Epub 2013 May 23. Fortschr Neurol Psychiatr. 2013. PMID: 23702802 Review.
Evidence-based pharmacotherapy of schizophrenia.
Leucht S, Heres S, Kissling W, Davis JM. Leucht S, et al. Among authors: heres s. Int J Neuropsychopharmacol. 2011 Mar;14(2):269-84. doi: 10.1017/S1461145710001380. Epub 2011 Jan 6. Int J Neuropsychopharmacol. 2011. PMID: 21208500 Free article. Review.
Maintenance treatment with antipsychotic drugs for schizophrenia.
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Leucht S, et al. Among authors: heres s. Cochrane Database Syst Rev. 2012 May 16;(5):CD008016. doi: 10.1002/14651858.CD008016.pub2. Cochrane Database Syst Rev. 2012. PMID: 22592725 Updated. Review.
87 results